Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
- The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
- The development and manufacturing agreement leverages Lonza’s global network of process development and GMP-manufacturing facilities across Europe and the US.
- The partnership utilizes Lonza’s novel milestone business model designed to support biotech companies and their investors by aligning deliverables, cash flow and value generation.
Quote from Jonathan Freeman, PhD, Co-Founder and COO, Anthos Therapeutics:
“Our partnership with Lonza provides Anthos Therapeutics access to its world-class development and manufacturing expertise. The integrated drug substance, drug product and labeling/packaging offering enables efficiency and speed to accelerate patient access to this potentially life-preserving therapy. Importantly, Lonza’s value-based milestone-driven business model addresses the product, timeline and financial needs of our company and our investors.”
Quote from Karen Fallen, President, Head of MMDM, Lonza:
“Partnering with Anthos Therapeutics reinforces the value of our milestone business model designed to meet the unique needs of virtual biotechs and their investors. We recognize that innovative funding and partnership approaches are necessary to help bring vital medicines to patients. By leveraging this model, together with our end-to-end IbexTM Develop offering, we can help virtual and small biotech-companies accelerate bringing drugs to patients, navigate demand uncertainty and reduce investment risks.”
Basel, Switzerland, 11 June 2020– Lonza announced today a partnership agreement with Anthos Therapeutics, a biotech created by Blackstone Life Sciences and Novartis. The partnership supports the development and manufacturing of Abelacimab, a novel, fully human, Factor XI and XIa antibody, which could, if approved, address a range of thrombotic disorders.
The life science industry is experiencing unprecedented innovation driven by rapid advancements in science and technology. Innovative business models, new modalities and strong partnerships play a critical role in accelerating the clinical development process and speeding up patients’ access to those essential drugs.
Lonza’s integrated end-to-end offering, developed specifically for virtual biotechs and their investors, responds to those unique needs. The company’s milestone business model is designed to deliver quality with agility and speed while maintaining an investor focus that aligns Anthos Therapeutics’ investment to value creation by Lonza. With drug substance and drug product capabilities under one quality system and a dedicated team working on Abelacimab from start to finish, the program aims to bring products to market faster while reducing investment risk. Lonza will utilize its global network of facilities in Basel, Stein and Visp, Switzerland, Slough, UK and Tampa, USA.
Thrombotic disorders are estimated to account for one in four deaths and are among the leading causes of mortality worldwide. A large unmet medical need exists for novel anti-thrombotic therapies, especially in patients currently underserved by conventional anti-coagulant therapies due to the risk of bleeding. As a promising next-generation anti-thrombotic with a unique dual Factor XI / XIa inhibitory activity, Abelacimab has the promise to be the first hemostasis-sparing anti-coagulant that may reduce pathological thromboembolic via a mechanism uncoupled from the required, physiological haemostatic pathway.
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
About Anthos Therapeutics
Anthos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated therapies for high-risk cardiovascular patient populations. Anthos’ most advanced program is Abelacimab (MAA868), an anti- Factor XI / XIa monoclonal antibody, which represents a promising next generation anti-thrombotic investigational therapy with the potential to prevent multiple thrombotic diseases with minimal or no bleeding risk. Anthos, located in Cambridge, Massachusetts.
Lonza Contact Details
Dr. Sanna Fowler
Lonza Group Ltd
Tel +41 61 316 8929
Lonza Group Ltd
Tel +41 79 421 1609
Anthos Therapeutics Contact Details
Dr. Jonathan Freeman
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.